$136 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 35 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 133.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $19,161,380 | +70.4% | 290,500 | +33.6% | 14.12% | +104.0% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $6,969,600 | -15.6% | 330,000 | +1.7% | 5.13% | +1.0% |
| KURA | Buy | KURA ONCOLOGY INC. COMMON STOCK | $6,913,093 | +11.1% | 565,257 | +12.7% | 5.09% | +33.0% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $5,104,740 | +0.3% | 298,000 | +14.6% | 3.76% | +20.1% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC | $4,371,570 | -14.7% | 121,500 | +5.7% | 3.22% | +2.1% |
| New | IVERIC BIO INCcall | $3,649,500 | – | 1,500 | +100.0% | 2.69% | – | |
| New | CELLDEX THERAPEUTICS INCput | $3,598,000 | – | 1,000 | +100.0% | 2.65% | – | |
| ARGX | Buy | ARGEN SEsponsored adr | $3,574,533 | +85.0% | 9,594 | +88.1% | 2.63% | +121.4% |
| FDMT | New | 4D MOLECULAR THERAPEUTICS INC | $1,800,704 | – | 104,753 | +100.0% | 1.33% | – |
| ALKS | New | ALKERMES PLC | $893,313 | – | 31,689 | +100.0% | 0.66% | – |
| New | ENLIVEN THERAPEUTICS INC | $678,440 | – | 30,979 | +100.0% | 0.50% | – | |
| SVRA | New | SAVARA INC | $388,110 | – | 199,031 | +100.0% | 0.29% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $233,100 | – | 14,000 | +100.0% | 0.17% | – |
| New | HILLEVAX INC | $110,156 | – | 6,664 | +100.0% | 0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.